Please select a community
Automation & Microfluidics
Biologics & Bioprocessing
Chemical Process Scale Up
Food & Beverage Analysis
Forensic Science & Clinical Toxicology
Genotyping & Gene Expression
LIMS & ELNs
Metabolomics & Lipidomics
Molecular & Clinical Diagnostics
Next Gen Sequencing
Stem Cells, Cellular Therapy & Biobanking
Become a Member
Add My Services
New MCO-170AIC CO2 incubator from Panasonic demonstrates exceptional control and optimises cell culture productivity
Monday, June 09, 2014
New MCO-170AIC CO2 incubators from Panasonic deliver outstanding quality in performance, maximise cell culture efficiency and provide optimum results and reproducibility. Designed specifically for the safe, consistent cultivation of successful cell lines, this latest innovation offers the very highest levels of precision, security and ease of use.
Nanobiotix Presents Successful Phase I Results for NBTXR3 at ASCO
Tuesday, June 03, 2014
Final results demonstrate a very good safety, treatment feasibility and promising signs of efficacy in patients with advanced Soft Tissue Sarcomas.
Debiopharm Moves Forward Three of its Oncology Clinical Programs
Thursday, May 29, 2014
Company will present the recent progresses at the 50th American Society of Clinical Oncology Annual Meeting.
Completion or Enrollment in the Phase III Confirmatory Study of KIACTA™
Thursday, May 29, 2014
KIACTA™ Phase III Confirmatory Study expected to be completed in 2016.
Sciformix to Reveal Strategic Model for Talent Acquisition at the DIA 50th Annual Meeting
Thursday, May 22, 2014
New career strategy aims to address talent acquisition and retention requirements for capacity expansion.
Aptiv Solutions Improves Accuracy of Dose Escalation Studies with Launch of ADDPLAN® DF 3.0
Friday, May 16, 2014
ADDPLAN® DF 3.0 incorporates complex statistical methodologies to prevent under and over-estimation of a therapeutic’s maximum target dose (MTD) during Phase I dose escalation trials.
Da Volterra's DAV132 Shown As Promising Candidate for Preventing Severe C. Difficile Infections
Tuesday, May 13, 2014
The CL1001 clinical trial also demonstrated the adequate targeted delivery of DAV132 to the ileum and the colon and its adsorbing effects.
Cleanroom Services Partnership Brings Synergy for Customers
Thursday, May 01, 2014
Two award-winning laboratory service providers have joined forces to create greater synergy for customers.
Quotient Clinical Extends its Translational Pharmaceutics™ Platform
Friday, April 25, 2014
Company will employ its manufacturing capabilities to supply specialist oncology centers with drug products.
Showing Results 21 - 30 of 309
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Researchers Find Key Player in Diabetic Kidney Disease Through Power of Metabolomics
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Early Antiretroviral Therapy Prevents Non-AIDS Outcomes in HIV-infected People
NIH-supported findings illustrate manifold benefit of therapy.
Adaptimmune’s NY-ESO-1 TCR-engineered T-Cells Demonstrate Durable Persistence
Study has been published in Nature Medicine.
Advertise On This Site
Terms & Conditions
©2015 Technology Networks
, all rights reserved.
Latest presentations and webinars
2,400+ scientific and medical posters
3,700+ scientific videos
JOIN TECHNOLOGY NETWORKS PREMIUM FREE!